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Abstract
Background: Oncogene overexpression in primary cells often triggers the induction of a cellular safeguard response
promoting senescence or apoptosis. Secondary cooperating genetic events are generally required for oncogene-induced
tumorigenesis to overcome these biologic obstacles. We employed comparative genomic hybridization for eight
genetically engineered mouse models of mammary cancer to identify loci that might harbor genes that enhance
oncogene-induced tumorigenesis.
Results: Unlike many other mammary tumor models, the MMTV-Myc tumors displayed few copy number variants
except for amplification of distal mouse chromosome 11 in 80 % of the tumors (syntenic to human 17q23-qter often
amplified in human breast cancer). Analyses of candidate genes located in this region identified JMJD6 as an epigenetic
regulatory gene that cooperates with Myc to enhance tumorigenesis. It suppresses Myc-induced apoptosis under
varying stress conditions through inhibition of p19ARF messenger RNA (mRNA) and protein, leading to reduced levels
of p53. JMJD6 binds to the p19ARF promoter and exerts its inhibitory function through demethylation of H4R3me2a.
JMJD6 overexpression in MMTV-Myc cell lines increases tumor burden, induces EMT, and greatly enhances tumor
metastasis. Importantly, we demonstrate that co-expression of high levels of JMJD6 and Myc is associated with poor
prognosis for human ER+ breast cancer patients.
Conclusions: A novel epigenetic mechanism has been identified for how JMJD6 cooperates with Myc during
oncogenic transformation. Combined high expression of Myc and JMJD6 confers a more aggressive phenotype in
mouse and human tumors. Given the pleiotropic pro-tumorigenic activities of JMJD6, it may be useful as a prognostic
factor and a therapeutic target for Myc-driven mammary tumorigenesis.
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Background
Tumorigenesis is a multistep process involving the accu-
mulation of genetic aberrations. Initiating oncogenic al-
terations promote the selection of additional genetic and
epigenetic changes that favor transformation, tumor
growth, and metastases. Initiating oncogenic alterations
in untransformed cells in most, if not all cases, trigger
cellular safeguard mechanisms that induce cellular sen-
escence (e.g., Ras) or apoptosis (e.g., Myc, E2F1, or
E1A). Therefore, oncogene-induced tumorigenesis gen-
erally requires cooperating genetic events to overcome
these safeguard mechanisms.
It has been firmly established that many genetically
engineered mouse models (GEMs) of mammary cancer
are valuable systems to dissect tumorigenic pathways
that may involve multiple genetic aberrations. Many
models have been designed to mimic human breast can-
cer by either overexpression of known oncogenes (Myc,
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Ras, Wnt, PyMT, Erbb2) or deletion of tumor suppressor
genes (BRCA1/2, p53, and Rb) [1, 2]. For example, sev-
eral mouse models of breast cancer, including MMTV-
PyMT or WAP-Myc, express markers associated with
human luminal-type breast cancer [3]. Murine models
(C3(1)-Tag or BRCA1 deficiency together with p53 mu-
tation) allow tumor development with a characteristic
basal-like phenotype [1, 3–5]. On the other hand, some
other models show mixed features and high levels of
heterogeneity [3]. Unlike human breast cancers, many
mouse models of mammary cancer are based upon the
induction of a specific oncogenic event through the
overexpression of relevant oncogenes or inactivation of
tumor suppressor genes, leading to the evolution of
oncogene-specific secondary pathways.
A predominant mechanism leading to additional gen-
etic alterations required for progression of tumorigenesis
appears to be related to changes in genome copy num-
ber variants (CNV). A recent study demonstrated that
22 % of the haploid genome in breast cancer is affected
by chromosome rearrangements [6], thus indicating that
CNVs are the major contributor to the accumulation of
additional genetic changes during tumor progression.
Array comparative genomic hybridization (CGH) has
been a powerful tool to identify chromosomal regions
that may harbor amplified oncogenes or deleted tumor
suppressor genes. These techniques combined with gene
expression analysis, revealed a significant correlation be-
tween human and multiple GEM models of mammary
gland tumors [3, 7, 8]. Recently 662 regions of chromo-
somal aberrations conserved between human and mouse
breast cancers were identified [8]. These studies allow
not only the identification of novel drivers of tumorigen-
esis but also find supporting genetic alterations neces-
sary for promoting cellular transformation and tumor
progression.
We used array CGH to identify CNVs in eight genetic-
ally engineered mouse models of mammary cancer to
find recurrent CNVs that potentially could harbor crit-
ical genes enhancing oncogene-induced transformation.
We determined that the distal region of chromosome 11
was amplified in 80 % of MMTV-Myc-driven mouse
mammary gland tumors. This locus is syntenic to hu-
man chromosome 17q23-qter, a region that is often
amplified in human breast cancers. We hypothesized
that gene(s) located in this locus are critical for Myc-
induced tumor development and progression. Myc is
commonly amplified in many cancers of different ori-
gins. Importantly, Myc is overexpressed in 25–30 % of
all breast cancer cases [9–12].
Further functional analyses of several candidate genes
overexpressed in the mouse 11q locus revealed that the
epigenetic modifier JMJD6 is able to inhibit Myc-induced
apoptosis, which is critical for tumor progression. While
Myc-triggered cell death may involve several pathways,
the predominant responder to aberrant induction of Myc
in primary cells is p19ARF and upregulation of p53. We
found that JMJD6 represses p19ARF, at least in part, by
demethylation of Arg3 of histone H4 associated within the
p19ARF promoter. Therefore, JMJD6 amplification may
cooperate with Myc to enhance neoplastic transformation
of primary epithelial cells. Additionally, when overex-
pressed in MMTV-Myc-driven tumor cells that lack the
11q amplification, JMJD6 induces EMT, increases cell mi-
gration and invasion in vitro, and stimulates tumor growth
in vivo. Most importantly, JMJD6 dramatically increased
lung metastatic colonization of these otherwise non-
metastatic cells. Bioinformatics analyses of human breast
cancer tumors revealed a significant decrease in survival
of patients with ER+ tumors when Myc and JMJD6 were
highly expressed together as compared to high Myc ex-
pression alone.
Identification of JMJD6 as a gene that cooperates with
Myc to enhance tumorigenesis could provide a novel
therapeutic target for breast and other cancers where
Myc is an essential driver of tumorigenesis, since to date
no successful therapies directly targeting Myc have been
developed.
Results
Identification of a chromosome 11 amplicon as the major
genomic alteration in MMTV-Myc mammary tumors
We performed comparative genomic hybridization
(CGH) of mammary gland tumors from eight genetically
engineered mouse models to identify genomic loci con-
taining genes with altered expression that potentially
cooperate with oncogenes or suppressor genes in pro-
moting tumorigenesis. On average, DNAs from 5–6
non-necrotic tumor samples from each model were ana-
lyzed by array CGH using the Agilent 44K array plat-
form. Spleen DNA from the background strain served as
the corresponding control. Our CGH results identified
previously reported copy number variants (CNVs) and
chromosomal aberrations in these models [8, 13–16],
validating the results. In addition to the amplification of
distal chromosome 6 in C3(1)-Tag model that we had
previously reported [17], we identified amplification of
chromosome 6 in four additional tumor models, gain of
partial or whole chromosome 15 in four models, and
loss of chromosome 4 in some C3(1)-Tag-driven tumors
(Fig. 1), consistent with prior reports [8, 13, 15, 16, 18].
Interestingly, 80 % of MMTV-Myc-driven tumors exhib-
ited minimal genomic changes except for amplification
of the distal part of chromosome 11. We also ob-
served this amplification in some MMTV-PyMT and
BRCA−/−; p53+/− tumors as have been previously re-
ported [8, 13, 15, 16]. However, these two models
also exhibited other large regions of chromosomal
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amplifications. Therefore, we chose to focus on the
MMTV-Myc model since the chromosome 11 amplifi-
cation region likely contains genes required for Myc
tumorigenesis. Importantly, this region is syntenic to
human chromosome 17q23-qter, which is often ampli-
fied in human breast cancer patients [19–22].
Identification of genes overexpressed in the chromosome
11 amplicon in MMTV-Myc mammary tumors
To gain more insight into the function of the genes lo-
cated in this region, we determined the minimal region
that was amplified in chromosome 11 across the
MMTV-Myc tumors and found that it contained 246
genes and one microRNA. The exact chromosomal co-
ordinates for those genes are presented in Additional file
1: Figure S1. To identify the genes that had higher ex-
pression in MMTV-Myc tumors compared to normal
mammary gland tissue or tumors from other models
that did not contain the chromosome 11 amplification,
we performed microarray analysis using RNA from nor-
mal glands as well as several mammary gland tumors de-
rived from MMTV-HRas and MMTV-Her2/Neu mice
(Fig. 2). Using these data together with a literature-based
screen of known gene functions, we selected seven genes
from the chromosome 11 candidate interval for further
validation (FBF1, Ube2o, TK1, Birc5, Sumo2, Tnrc6c,
and JMJD6).
To identify potential candidate cell lines derived from
MMTV-Myc tumors for further in vitro studies, we
performed CGH analysis of several cell lines and found
that the Myc83 cell line harbors the chromosome 11
amplicon, as previously observed [23], while the 88CT1
cell line has relatively few CNVs without amplification of
the chromosome 11 locus (Additional file 1: Figure
S2A). We also found increased expression levels of se-
lected genes (JMJD6, Tnrc6c, and Ube2o) by RT-qPCR
in the Myc83 cells compared to 88CT1 cells, consistent
with the status of the chromosome 11 amplification
(Additional file 1: Figure S2B).
Identification of JMJD6 as a gene that suppresses Myc-
induced apoptosis
Since Myc expression increases apoptosis in primary
cells, which is a major response preventing full trans-
formation of cells by Myc alone, we tested the hypoth-
esis that the increased expression of candidate genes
would suppress Myc-induced cell death, whereas deple-
tion of any of the seven selected genes would increase
Myc-induced cell death in vitro. Myc-induced apoptosis
in many cases requires an intact p53 pathway. Sequence
analysis confirmed the wild-type status of p53 in both
Myc83 and 88CT1 cells. However, etoposide treatment
of these cell lines revealed that Myc83 responded to eto-
poside with a robust increase in p53 and p21 protein
levels, while 88CT1 had a much lower expression of p53
(possibly because of the amplification of MDM2 in these
cells, as determined by CGH analysis). Therefore, for the










Fig. 1 DNA copy number analysis. Array CGH analysis of mouse mammary gland tumors from eight genetically engineered models of breast
cancer. 5–6 tumors were used for each model. The threshold line is drawn at 35 % of samples. Genomic regions of significant gains are shown in
blue and significant losses are shown in red. Arrow indicates the amplification of distal mouse chromosome 11
Aprelikova et al. Clinical Epigenetics  (2016) 8:38 Page 3 of 16
express high constitutive levels of c-Myc and contain the
chromosome 11 amplification. The limitation of this
model is that one cannot conclude that cell death is
Myc-dependent or whether the tested genes have a more
general effect on cell viability.
To clarify this question, we established another model
using normal murine mammary gland (NMuMG) epi-
thelial cells with inducible expression of MycER™ where
c-Myc is fused in frame with the mutated estrogen
receptor-binding domain which makes it refractory to
beta-estradiol but that can be activated by the addition
of 4-hydroxytamoxifen [24]. First, we tested five different
small hairpin RNA (shRNA) constructs for each gene
and selected those that provided at least a 50 % reduc-
tion in gene expression. These shRNAs were then stably
expressed in Myc83 cells and NMuMG-MycERTM cells
and the resultant cells were treated with etoposide or
glucose deprivation. As shown in Fig. 3 and Additional
file 1: Figure S3, the most consistent increase in Myc-
dependent cell death in both cell types was obtained
after depletion of JMJD6. The efficiency of JMJD6
knock-down by two shRNAs is shown in Additional file
1: Figure S4. Several other genes showed promising re-
sults in cooperation with Myc in MNuMG cells (FBF1)
and others in Myc83 cells (Sumo2), which may reflect
limited cell type-specific functions of these genes. We,
therefore, focused on exploring the cooperation of
JMJD6 with c-Myc in cellular transformation, tumor
progression, and metastases.
The anti-apoptosis effect of JMJD6 is dependent upon
JMJD6 enzymatic activity
JMJD6 is an enzyme with pleiotropic functions that has
been recently implicated in the breast, and some other
cancers where high expression of JMJD6 was an indica-










Fig. 2 Gene expression microarray analysis for chromosome 11
amplified region. The heatmap shows the differential gene expression
in mammary gland tumors from MMTV-Myc transgenic mice with
chromosome 11 amplification versus MMTV-Her2, or MMTV-HRas
tumors lacking the chromosome 11 amplification, or normal lactating
mammary glands from FVB/N mice. Genes labeled in red are expressed
at higher than median levels and genes labeled in green are expressed
at lower than median levels. Genes selected for further validation are
indicated on the left side
A
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Fig. 3 Analysis of cell death induced by glucose deprivation or
etoposide treatment in cells with JMJD6 knock-down. a Myc83-
derived cell lines (parental line from a MMTV-Myc tumor) with stable
expression of two independent shRNAs targeting JMJD6 or with
empty vector (EV) control were treated with 100 μM etoposide or
grown in glucose-free media for 20 h. Cell death was measured
using CytoTox-Glo reagent. The experiments were repeated 3 times
and the percentage of dead cells in each experiment was expressed
relative to control (EV) cells. b NMuMG cells with MycER™ and
shJMJD6 expression were first treated with 150 nM 4-OHT (MycON)
or ethanol (MycOFF) for 24 h to activate Myc and then treated as in
a Black bars—MycOFF (ethanol-treated cells), open bars—MycON (4-
OHT-treated cells). Results were normalized to EV control with
MycOFF. *p < 0.05, **p < 0.01
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model system using NMuMG cells with constitutive
overexpression of JMJD6 and an inducible c-Myc. As ex-
pected, ectopically expressed JMJD6 was localized to cell
nuclei whereas control cells exhibited ectopic cytoplas-
mic expression of LacZ (Additional file 1: Figure S5A).
The overall levels of JMJD6 in transfected cells were
close to physiological levels observed in cells with ampli-
fied chromosome 11 (about 3-fold over control cells,
Additional file 1: Figure S5B). Cells expressing high
levels of c-Myc proved to be sensitive to multiple stress
conditions, including depletion of nutrients or growth
factors, or treatment with DNA-damaging agents, lead-
ing to cell death. C-Myc induction in NMuMG cells
followed by exposure to four different stress conditions
resulted in a significant increase in cell death, which was
reduced by co-expression with JMJD6 (Fig. 4a–d).
JMJD6 is an iron- and 2-oxoglutarate-dependent dioxy-
genase with the capability to hydroxylate lysine residues in
histone and non-histone proteins [26, 29, 30]. Lysine hy-
droxylation of RNA splicing factors results in production
of differentially spliced pre-messenger RNA (mRNA) mol-
ecules [31], while hydroxylation of histone proteins may
result in changes in transcriptional regulation of targeted
gene expression [32]. In order to determine whether the
enzymatic activity of JMJD6 is necessary for the inhibition
of Myc-induced cell death, we mutated His187 to Ala in
the iron-coordinating center of the enzyme that has previ-
ously been showed to inactivate JMJD6 and demonstrated
that mutant JMJD6 does not suppress cell death (Fig. 4e).
Western blotting confirmed that the levels of mutated
protein expression were similar to the expression of the




Fig. 4 Overexpression of wild-type, but not mutated, JMJD6 suppresses Myc-induced cell death in response to different stress conditions. NMuMG
cells stably expressing MycERTM or empty pBabe vector were transduced with JMJD6-V5 or LacZ-V5 control. Cells were treated with 4-OHT or
ethanol as in Fig. 3 and placed in glucose-free (a), serum-free (b), or glutamine-free (c) media or treated with etoposide (d) for another 20 h. Cell
death was measured as in Fig. 3. Black bars—MycOFF, open bars—MycON. e Catalytically inactive JMJD6H187A (JMJD6mut) is not able to
suppress Myc-induced cell death. *p < 0.05, **p < 0.01. f Western blot analysis shows equal ectopic expression of JMJD6 or mutated JMJD6 in
NMuMG cells with our without Myc expression
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To further prove that high levels of wild-type JMJD6,
but not its mutated form, inhibit cell death, we exam-
ined protein levels of cleaved caspase 3 and PARP
(markers of apoptosis) following Myc induction and ex-
posure to different stress conditions. While control cells
showed robust cleavage of both enzymes upon c-Myc
induction, cleavage was clearly diminished when cells
co-expressed wild-type JMJD6 (Fig. 5). However, the ex-
pression of mutant JMJD6 had a minimal effect on sup-
pressing caspase 3 and PARP cleavage, which remained
similar to levels observed in control cells (Fig. 5).
In order to understand mechanisms by which JMJD6 in-
hibits Myc-induced cell death, we first analyzed its effect
on Myc protein levels and cellular localization. Additional
file 1: Figure S5A shows that MycER™ or endogenous
levels of c-Myc were not compromised by overexpression
of JMJD6. Also, in the presence of 4-hydroxytamoxifen,
ectopically expressed MycER™ re-localizes to the cell nu-
cleus similar to control cells without JMJD6 overexpres-
sion (Additional file 1: Figure S6B).
Identification of mechanisms contributing to JMJD6
inhibition of Myc-induced apoptosis
We then sought to establish which pathways involved in
Myc-induced cell death are inhibited by elevated levels
of JMJD6 expression. In many cellular models, Myc-
induced apoptosis stimulates induction of p19ARF that
sequesters MDM2 ubiquitin ligase, allowing for the
upregulation of p53 that activates apoptotic pathways
[33–35]. We first found that in NMuMG cells, JMJD6
downregulates the endogenous levels of p19ARF and
p53, with or without c-Myc induction (Fig. 6a). It has
been known that p19ARF may be suppressed by Bmi1
protein; however, we found no difference in Bmi1 pro-
tein levels in cells with high expression of JMJD6
(Fig. 6a). We also analyzed p19ARF and p53 induction
after treatment with the DNA-damaging agent etoposide
in the presence of JMJD6. JMJD6 expression resulted in
lower levels of p19ARF, p53 total protein, and its Ser18
phosphorylated form as well as p21 proteins at all time
points after etoposide treatment, compared to LacZ con-
trol (Fig. 6b).
Our finding that JMJD6 may reduce p19ARF stimula-
tion by Myc led us to determine whether the blunting ef-
fect of JMJD6 on Myc-induced cell death is p19ARF
dependent. We overexpressed p19ARF protein in cells
with JMJD6 and the inducible MycERTM and determined
levels of cell death after starving cells in serum-free condi-
tions. Indeed, increased levels of p19ARF protein rescued
Myc-induced apoptosis in cells with high JMJD6 expres-
sion, demonstrating that p19ARF suppression by JMJD6
contributes to the alleviation of cell death (Fig. 6c, d).
To further confirm that high expression of JMJD6
would correlate with decreased expression of p19ARF in
vivo, we analyzed expression of these two genes in
mouse MMTV-Myc mammary gland tumors. This ex-
periment also showed robust negative correlation be-
tween JMJD6 and p19ARF (Additional file 1: Figure S7).
JMJD6 reduces p19ARF expression through histone H4
modifications on the p19ARF promoter region
JMJD6 is involved in post-translational modifications of
non-histone and histone proteins [29, 30, 32, 36]. How-
ever, when JMJD6 regulates histone modifications, it
modifies mRNA levels of the target gene. To discrimin-
ate which of the pathways is involved in p19ARF
Fig. 5 Western blot analysis of apoptotic markers in Myc-induced cells in the presence of wild-type or mutated JMJD6. NMuMG cells were treated
with 150 nM 4-OHT to induce Myc or ethanol and placed in glucose- or glutamine-free media or treated with 100 mM of etoposide. Expression
of cleaved PARP and cleaved caspase 3 was determined by Western blot demonstrating reduced levels in the presence of wild-type, but not
mutant, JMJD6
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silencing by JMJD6, we studied p19ARF transcript levels
in the presence of high JMJD6 expression. We clearly
observed that JMJD6 overexpression significantly reduces
mRNA levels of p19ARF (Fig. 6e), while three different
JMJD6 shRNA constructs significantly increased p19ARF
mRNA when expressed in NMuMG cells (Fig. 6f).
Previously published data suggest that JMJD6 is able to
remove methyl groups from symmetrically (H4R3me2s)
or asymmetrically (H4R3me2a) methylated arginines
[32, 36]. This allows JMJD6 to act as a transcriptional
activator or repressor, as H4R3me2s modification is
associated with repressed chromatin [37, 38] and
H4R3me2a is a mark for transcriptionally active chro-
matin [37, 39, 40]. To this end, we performed chro-
matin immunoprecipitation experiments to compare
the amounts of activating H4R3me2a associated with
the p19ARF promoter in cells expressing high levels
of JMJD6 versus cells with low expression of JMJD6.
First, we found that control cells expressing LacZ or
mutated JMJD6 have a significantly higher presence
of H4R3me2a within the p19ARF promoter than cells
with overexpression of JMJD6 (p = 0.01) (Fig. 7a). Fur-
thermore, chromatin immunoprecipitation with anti-
bodies specific for JMJD6 showed that JMJD6 as well
as mutated JMJD6 protein is bound to the p19ARF
promoter (Fig. 7b). We also analyzed JMJD6 effect on
p16 and found no expression of p16 in control or JMJD6-
overexpressing NMuMG cells by RT-qPCR or Western
blotting. Therefore, to prove specificity of anti-JMJD6
antibody in ChIP assay, we used p16 promoter primers
and found no binding of JMJD6 to p16 promoter
(Additional file 1: Figure S8). In addition, since control
LacZ, JMJD6, and JMJD6 mutants were fused with C-





Fig. 6 JMJD6 overexpression reduces p53 and p19ARF levels. a Immunoblotting of NMuMG cells with ectopic expression of JMJD6 or LacZ
control shows decreased protein levels of p53 and p19ARF in cells with or without Myc induction. b Cells were stimulated with 4-OHT to induce
Myc and then treated with 100 mM etoposide for 4 and 8 h to analyze p53 induction. Immunoblots show lower levels of p53 or Ser18-
phosphorylated p53 as well as p19ARF and p21 in cells expressing JMJD6. Intensity of each band normalized to β-actin was obtained using
ImageJ software. c Overexpression of p19ARF in the presence of JMJD6 restores Myc-induced cell death. NMuMG cells expressing MycER™
together with JMJD6, LacZ, or JMJD6 plus p19ARF were treated with 4-OHT (MycON) or ethanol (MycOFF) for 24 h and placed in serum-free
media for another 24 h. Percentage of dead cells was measured with CytoTox-Glo reagent. Black bars—MycON, open bars—MycOFF. d Western
blot analysis of NMuMG cells with ectopic overexpression of p19ARF. e RT-qPCR analysis shows that overexpression of JMJD6 in NMuMG cells
inhibits p19ARF transcription. Black bars—NMuMG cells expressing LacZ control, open bars—cells expressing wild-type JMJD6. f Knock-down of
endogenous JMJD6 with three different shRNAs increases mRNA levels of p19ARF
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conjugated agarose and confirmed higher abundance of
JMJD6 and JMJD6 mutant binding to the p19ARF pro-
moter compared to LacZ control (Fig. 7c).
Since endogenous mouse JMJD6 is poorly recognized
by the antibody available for ChIP studies, we decided to
test human HeLa cells to analyze whether endogenous
JMJD6 in these cells is found on the ARF promoter. We
tested the human p14ARF promoter with two primer
sets using a human JMJD6 antibody for ChIP and found
higher levels of JMJD6 associated with the ARF pro-
moter compared to immunoprecipitation with a non-
specific IgG (Fig. 7d). In summary, we found that in
non-tumorigenic mouse epithelial cells, JMJD6 may
collaborate with c-Myc to initiate tumor formation by
suppressing Myc-induced cell death by inhibiting
transcriptional expression of the p19ARF tumor sup-
pressor protein.
JMJD6 promotes Myc-induced tumor formation
We sought to determine to what extent established
mammary tumors remain dependent on JMJD6 expres-
sion for tumor maintenance and an aggressive pheno-
type. We first knocked down JMJD6 in Myc83 cells with
elevated JMJD6 expression using two different shRNAs
and found a significant delay in tumor formation com-
pared to control cells when injected into mouse mam-
mary fat pad (Fig. 8a). To show the reciprocal effect of
increased JMJD6 expression in low JMJD6-expressing
cells, overexpression of JMJD6 in 88CT1 cells resulted
in significantly larger tumors compared to LacZ control-
expressing cells (Fig. 8b). The tumors derived from
88CT1 cells ectopically expressing JMJD6 exhibited sig-
nificantly less apoptosis by TUNEL assay (Fig. 8c) than
control cells but no difference in expression of the cell
proliferation marker Ki67 (Fig. 8d).
Interestingly, we demonstrated that 88CT1 cells estab-
lished from MMTV mice have a compromised p53 path-
way, possibly resulting from amplification of MDM2 (gain
of 8 copies) as determined by array CGH. We found that
the reduction in the percentage of apoptotic cells in
88CT1 cells overexpressing JMJD6 was associated with el-
evated levels of the Bcl2 anti-apoptotic family members
Bcl-xl and Bcl-w (Fig. 8e) that were previously shown to
inhibit Myc-induced cell death [41–43].
JMJD6 enhances cell migration, invasion, and metastases
MMTV-Myc mammary gland tumors usually produce
well-differentiated tumors with a relatively long latency
and relatively few metastases [12, 44, 45], implying that
additional genetic alterations are required for a more ag-
gressive phenotype. However, several observations raise
the possibility that elevated expression of Myc protein
may inhibit cellular migration, invasion, and metastasis
formation in mouse xenograft models of breast cancer
[46]. We therefore investigated whether JMJD6 might
enhance migration, invasion, and metastases of MMTV-
Myc mammary tumor cells.
Ectopic expression of JMJD6 in 88CT1 cells resulted
in a 2–3-fold increase in motility and invasion compared
to non-JMJD6-expressing cells using the Boyden cham-
ber assays (Fig. 9a, b) and was associated with increased
expression of the EMT markers Snail and Twist1, while
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Fig. 7 JMJD6 binds to the p19ARF promoter and decreases histone H4R3 asymmetric dimethylation of the p19ARF promoter. ChIP analysis of the
p19ARF promoter in NMuMG cells expressing LacZ, JMJD6, or JMJD6 mutant using immunoprecipitation with a anti-H4R4me2a, b anti-JMJD6
antibody, c V5-conjugated agarose. d ChIP analysis of HeLa cells shows binding of endogenous JMJD6 to the human p14ARF promoter. Two
different primer sets (distal and proximal) were used for qPCR after immunoprecipitation. Primers for human β-globin gene promoter were used
as a positive control
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Fig. 8 JMJD6 promotes tumor growth of cells derived from MMTV-Myc mammary gland tumors. a 106 Myc83 cells (with amplification of the
chromosome 11 locus containing JMJD6) stably expressing empty vector (EV) or two independent shRNAs targeting JMJD6 were injected into
mammary fat pads of FVB/N mice and tumors were measured over the next month. b 5 × 105 88CT1 cells (no chromosome 11 amplification) with
stable expression of LacZ control or wild-type JMJD6 were surgically implanted into mammary fat pads and tumor growth was measured over
the next 20 days. c Tumors from b were formalin fixed and sectioned and the percentage of dead cells was analyzed by TUNEL assay. d Tumors
from b were immunostained with anti-Ki67 antibodies and signal intensity was quantitated by ImageJ software. e Western blot analysis of pro-




Fig. 9 JMJD6 increases the metastatic propensity of c-Myc-expressing cells. Transwell migration (a) and invasion (b) assays of 88CT1 cells
overexpressing JMJD6 compared to LacZ control (*p < 0.05, **p < 0.01, respectively). c Western blot analysis of EMT markers in the cells used in
a and b shows increased expression of Snail and Twist1 in cells with high expression of JMJD6. d Lung colonization in vivo. 5 × 105 cells used in
a and b were injected by tail vein into FVB/N mice. After 20 days, the lungs were formalin fixed and stained with H&E. e Quantitation of
metastatic nodules per lung of mice shown in d
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others, vimentin and Slug, remained unchanged (Fig. 9c).
To test the metastatic propensity of 88CT1 cells overex-
pressing JMJD6, we injected those cells or LacZ control
cells via mouse tail vein and analyzed lung sections
21 days later. Control cells produced very few and in
many cases no metastatic nodules while cells with ele-
vated expression of JMJD6 showed a dramatic 20-fold
increase in the number of lung colonies (p < 0.0001,
Fig. 9d, e). These results demonstrate that JMJD6
contributes to Myc-induced mammary gland tumor
maintenance and confers a highly metastatic tumor
phenotype.
High expression of JMJD6 in human breast tumors is
associated with a worse prognosis of Myc-high tumors
The in vitro and in vivo results presented above suggest
that the combination of high expression of Myc and
JMJD6 might be associated with a poor clinical progno-
sis. To determine whether this might be true for human
breast cancers, we performed an in silico analysis using
the METABRIC database that contains microarray data
and clinical information on about 2000 breast cancer pa-
tients. All cases were divided into four subsets, consist-
ing of high/low, high/high, low/high, and low/low of
JMJD6/Myc expression. When we compared patients
with high versus low JMJD6 expression, we observed a
highly significant effect in samples with high Myc rather
than low Myc expression (compare p values for left and
right panels in Fig. 10a, c). We determined that high
JMJD6 expression is associated with a poor prognosis
for ER-positive breast cancer patients and not for ER-
negative breast cancer (Fig. 10b), consistent with a previ-
ous report analyzing JMJD6 expression as a biomarker
for poor prognosis in ER+ breast cancer [25]. Overall,
this analysis predicts that JMJD6 gene expression may
be a discriminating factor for survival of patients with
high Myc expression in ER-positive breast cancer
patients.
Discussion
Our array CNV results of 8 GEM models of mammary
cancer demonstrated that there are common genomic
amplifications and losses in multiple models as well as
alterations that are more pronounced in specific models.
These data, consistent with prior reports, demonstrates
that the evolution of genomic alterations during tumori-
genesis in these models appears to depend upon the
genetic event that initiates transformation. We focused
on the MMTV-Myc model since Myc is overexpressed
in about 30 % of human breast cancers and this model
displays relatively few CNVs except for a prominent
amplification of mouse distal chromosome 11.
We identified several candidate genes within this locus
that could potentially cooperate with Myc and enhance
tumorigenesis. Functional analyses determined that the
epigenetic modifier JMJD6 cooperates with Myc to aug-
ment oncogenic transformation of normal mammary
epithelial cells as well as to increase the aggressiveness
and metastatic potential of Myc-driven tumors. In-
creased expression of JMJD6 resulted from the in vivo
selection for the amplification of the distal region of
chromosome 11 in Myc-overexpressing tumors. The
chromosome 11 amplified locus is not exclusively spe-
cific for Myc-driven tumors but also has been found in
mouse mammary gland tumors with overexpression of
Erbb2, PyMT, or BRCA1 mutations (this study and
[8, 13–16, 23]), which implicates JMJD6 as potentially
augmenting tumorigenesis in other oncogenic pathways.
Myc activation in normal cells is not capable of pro-
moting neoplastic transformation because of the over-
whelming induction of cell death triggered by Myc
protein expression above normal physiological levels
[47–51]. The mechanisms of Myc-induced apoptosis




Fig. 10 High expression of JMJD6 and Myc shows the worst prognosis
for human mammary gland tumors. a Kaplan-Meier survival curves are
shown for the high versus low expression of JMJD6 in the presence of
low (left panel) or high (right panel) expression of Myc. METABRIC
database (~2000 patients) was used to perform this analysis. Analysis was
performed as in a for b ER-negative or c ER-positive mammary
gland tumors
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pathways of Myc-dependent cell death and proliferation.
First, similar to other oncogenes, supraphysiological
levels of Myc induce p19ARF (p14ARF in human) that
sequesters MDM2 E3 ubiquitin ligase which leads to
stabilization of p53 [33, 35]. Consistent with this finding,
loss of p19ARF or p53 allows Myc to immortalize pri-
mary cells and synergize with Myc-induced tumorigen-
esis [52–54]. There is also evidence that ARF can limit
Myc activity by direct protein-protein interaction inde-
pendent of p53 and MDM2 [55, 56]. Therefore, ARF
mediates its tumor suppressor activity through p53-
dependent and -independent mechanisms to prevent
Myc-stimulated proliferation and cellular transform-
ation. In this study, we found that JMJD6 decreases
Myc-induced apoptosis, at least in part, by suppressing
p19ARF expression. It would be interesting to analyze
the cooperation of JMJD6 with other oncogenes whose
action is also restricted by ARF.
There are multiple functions assigned to the JMJD6
enzyme. It was first discovered as a histone arginine
demethylase [36] and a lysine hydroxylase of histone and
non-histone proteins [29, 30]. The function of JMJD6 as
an epigenetic modifier of histone proteins has been
widely debated in the literature. The unique property of
JMJD6 is its ability to function as an arginine demethy-
lase. Currently, it is the only known arginine demethy-
lase that is capable of targeting both histone and non-
histone proteins. In vitro studies have demonstrated the
removal of monomethyl groups from histone arginine
residues as well as symmetric and asymmetric methyl
groups [32, 57]. That implies that JMJD6 may function as
a transcriptional activator and transcriptional repres-
sor, as H4R3me2s (symmetric) is a repressive mark
[37, 38] and H4R3me2a (asymmetric) methylation is a
mark of active chromatin [37, 39, 40]. Consistent with
this notion, diminished expression of p19ARF in cells
with high JMJD6 levels presented in this study was
accompanied by a decrease in histone H4R3me2a
modification (a marker of active chromatin) in the
p19 promoter. This was associated with reduced p53
expression and reduced apoptosis.
Consequences of lysine hydroxylation of non-histone
proteins may be variable. For example, when JMJD6 hy-
droxylates splice factor U2AF65 [30, 58], it changes
VegfR1 mRNA splicing in endothelial cells in favor of
the angiogenesis promoting long form of the protein
[31, 59]. Another example of non-histone protein modi-
fication by JMJD6 has recently identified its ability to hy-
droxylate Lys382 in p53 protein in the colorectal cancer
cell line HCT116 [26]. This modification does not affect
p53 protein stability but rather inhibits its transcrip-
tional activity. This is, however, not the case for normal
mouse epithelial cells used in this study, as we clearly
see decreased p53 at the protein level (Fig. 6). We are
currently exploring the possibility that JMJD6 also in-
duces p53 hydroxylation in non-tumorigenic mouse and
human cells.
Several publications identified Brd4 as a binding partner
of JMJD6 in different cell types [32, 60, 61]. Brd4 is classi-
fied as a histone code “reader” that functions by recognition
of acetylated histones and recruiting epigenetic modifiers to
the target gene [62]. Assembly of the Brd4-JMJD6 complex
in distant enhancers of target genes stimulates histone
H4R3me2(s) demethylation as well as cap removal from
7SKsnRNA, promoting transcriptional activation regulated
by anti-pause enhancers [32]. Interestingly, Myc protein
was also implicated in the transcriptional pause release of
active genes [63]. When Myc levels were increased, similar
to Myc-amplified tumors, Myc also occupied distant en-
hancers of actively transcribed genes [64] which raises the
question of whether JMJD6 amplification in MMTV-Myc
tumors is necessary for the overall increase of transcrip-
tional activation by Myc. Further experimentation will be
required to fully understand the extent of Myc-JMJD6
cooperation.
Elevated levels of JMJD6 protein and mRNA were re-
ported for several tumor types, breast, lung, and colon
cancers [25–27]. For colon cancer, elevated JMJD6 ex-
pression positively correlated with depth of invasion,
lymph node metastasis, and advanced tumor node me-
tastasis stage [27]. In agreement with this, we observed a
causal role of JMJD6 in dramatically promoting metasta-
sis in Myc-driven tumors (Fig. 9).
Myc is a proto-oncogene that triggers tumorigenesis
by increasing cellular proliferation. However, paradoxic-
ally, it has been reported that in breast cancer cells, it
can act as a metastasis suppressor, decreasing cell inva-
sion in vitro and reducing metastatic burden in mice in
vivo [46]. In our experiments, overexpression of JMJD6
in MMTV-Myc tumor cells was able to dramatically in-
crease the number of metastatic nodules in lungs of
mice after tail vein injection, as well as invasion and mi-
gration of these cells in vitro. In addition, analysis of a
large cohort of breast cancer patients (more than 2000)
revealed that high JMJD6 expression in human breast
cancer with high Myc results in a lower overall survival
presumably due to a higher metastatic burden (Fig. 10).
This is consistent with a previous report that demon-
strated that high JMJD6 was associated with a worse
prognosis in ER+ breast cancer [25]. ERα function is reg-
ulated in part by methylation of R260, which is required
for estrogen-induced complex formation of ERα with
Src and PI3K and activation of the Akt pathway [65].
JMJD6 demethylates this R260me2a after treatment with
estrogen [57], which implies a compromised, non-
genomic function of ERα. However, it remains unclear
how JMJD6 expression leads to a worse prognosis in
ER+ patients.
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Conclusions
Our studies have revealed important cooperativity be-
tween JMJD6 and the Myc proto-oncogene and possibly
other types of oncogene-driven breast cancers. These re-
sults suggest that JMJD6 protein expression may be used
as a prognostic biomarker in future studies. Additionally,
since Myc is overexpressed in many breast cancers
but not successfully targeted by drugs, inhibiting




Genomic DNA was extracted from tumors or spleen (as
reference) from 8 GEM models of mammary cancer
using DNeasy Blood and Tissue kit (Qiagen, USA). Five
hundred nanograms of reference or test sample DNA
was labeled with Cy3 and Cy5 using Enzo CGH labeling
kit (Enzo Life Sciences, USA) according to the manufac-
turer’s instructions. The labeled DNAs were purified
with Amicon Ultra-0.5, 30Kd filters and hybridized to
Agilent 44K CGH arrays for 44 h at 65 °C in a rotating
microarray hybridization chamber and then washed with
buffer 1 for 5 min at room temperature and buffer 2 for
1 min at 37 °C. After a brief rinse in acetonitrile and
Agilent stabilizer (Agilent 5185–5979), the arrays were
scanned in an array holder covered with the ozone bar-
rier using the Agilent DNA microarray scanner G2539A.
The array features were extracted using the Agilent Fea-
ture Extraction v10.7. The copy numbers were analyzed
using Agilent Genomic Workbench 5.0 program and
Nexus Copy Number software (BioDiscovery, USA).
Data have been deposited to the Gene Expression
Omnibus (accession number GSE75331). The reviewer
access url is http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?token=yxclqmqynzadxgx&acc=GSE75331.
Gene expression microarray
Total RNA (1 μg) was reverse transcribed with a T7-
oligo(dT) primer and labeled with biotin using the
Affymetrix One Cycle Target Labeling kit (Affymetrix,
USA), following the manufacturer’s protocol. RNA was
then labeled and hybridized to the mouse genome 430A
2.0 GeneChip (Affymetrix, USA) and scanned on an
Affymetrix GeneChip scanner 3000. Data were collected
using Affymetrix GCOS software. Data analysis was de-
scribed in Zhu et al., 2011 [66]. Data have been depos-
ited to the Gene Expression Omnibus (accession
number GSE23938).
Cell lines
NMuMG epithelial cells were purchased from ATCC.
MMTV-Myc mammary gland tumor cell lines Myc83
and 88CT1 were obtained from Dr. R. Dickson
(Georgetown University). Cells were cultured in DMEM
(high glucose) tissue culture media, supplemented with
10 % fetal bovine serum (Life Technologies, USA) and
penicillin/streptomycin. Cultures were incubated in hu-
midified air containing 5 % CO2 at 37 °C. Cells in nutri-
ent deprivation experiments were cultured in DMEM
glucose-free, glutamine-free media (Life Technologies,
USA), supplemented with 10 % dialyzed FBS (dialyzed
against 3 changes of 100 volumes of PBS) [67]. The
remaining components (glucose or glutamine) were
added separately. 4-hydroxytamoxifen was purchased
from Sigma and used at a final concentration of 150 nM.
Etoposide (Sigma, USA) was added for 24 h at a final
concentration of 100 μM.
Plasmids
The lentiviral vectors pLenti6.2 expressing LacZ-V5 or
JMJD6-V5 were described by Lee et al. [25] and were a
kind gift of Dr. K. Desai (National Institute of Biomed-
ical Genomics, India). The pre-designed lentiviral
shRNA vectors for knock-down of JMJD6, TK1, Tnrc6c,
Sumo2, FBF1, Birc5, and Ube2o were cloned into MIS-
SION vector with puromycin resistance and purchased
from Sigma. PBabePuro-MycERTM used for Myc induc-
tion in cells overexpressing JMJD6 or LacZ was a gift
from Dr. G. Evan (UCSF), and pBabeHygro-MycERTM
used with shRNA knock-down experiments was a gift
from Dr. Y. Lazebnik (Cold Spring Harbor laboratory).
Retroviral vector pBabe-p19ARF was a gift from Dr. P.
Johnson (NCI).
Real-time quantitative PCR
Total RNA was isolated from cells by TRIzol extraction
(Life Technology). One microgram of total RNA was re-
verse transcribed in a 50-μl reaction using TaqMan Re-
verse Transcription Reagents (Life Technologies, USA)
according to manufacturer’s instructions. Five microli-
ters of the resultant reaction was PCR amplified in a
total volume of 20 μl for 40 cycles using an Applied Bio-
systems 7500 instrument. TaqMan probes were purchased
from Life Technologies. Mouse Tbp (TATA binding pro-
tein) was used as a standard for normalization. The gene
expression for p19ARF was also validated with the specific
pre-designed probe Mm.PT.58.8388138 (Integrated DNA
Technologies, USA) with SYBR Green qPCR master mix
(Bio-Rad, USA). All reactions were performed in triplicate.
Chromatin immunoprecipitation
For immunoprecipitation with anti-H4R3me2a anti-
body (Active Motif, USA) cells were fixed with 1 %
formaldehyde (Sigma, USA) for 15 min at room
temperature. For immunoprecipitation with anti-JMJD6
antibody (Millipore, USA), cells were first fixed with
2 mM disuccinimidyl glutarate (DSG) (ProteoChem,
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USA) for 45 min at room temperature, followed by two
washes with cold PBS and additional fixation with 1 %
formaldehyde for 15 min. ChIP assays were performed
using a ChIP-IT High Sensitivity Kit from Active Motif
(USA). Fixation was stopped by addition of 1/20 vol-
ume of stop buffer, and aliquots of 4 × 106 cells were
lysed in 400 μl of SDS-lysis buffer. DNA shearing was
performed for a total of 16 min at high power setting in
BIORUPTOR water bath sonicator (Diagenode, USA).
Immunoprecipitation was performed with 1.4 μg of
anti-JMJD6 or 10 μg of anti-H4R3me2a antibody or
40 μl of V5-agarose (Sigma) at 4 °C overnight. DNA
protein complexes were collected with protein G agar-
ose beads and washed according to manufacturer’s in-
structions. After elution and reversal of crosslinking,
samples were treated with RNase A and proteinase K
and purified with QIAQuick PCR columns. Five micro-
liters of the eluted DNA was used for quantitative PCR
analysis with SYBR Green qPCR master mix (Bio-Rad,
USA). For mouse p19ARF, primers used [68] were
forward primer 5′-TTCCAGGCCTTGCCATCTTCCT
AT-3′ and reverse primer 5′-TGGTCTGGCTGCAGT
AAAGTAGCA-3′. For human p14ARF, we used two
pairs of primers: distal forward 5′-CATTTCTGAGGA
AGGGCTACTT-3′ and distal reverse 5′-GCCACCT
TTCTGTCTAGTATGG-3′, proximal forward 5′-TCG
CCAAGACAACCATTCTAC-3′ and proximal reverse
5′-CGCTTCTTCCTCTTTCCTCTTC-3′. For amplifi-
cation of mouse p16 promoter, the primers were
forward 5′-CAGATTGCCCTCCGATGACTTC-3′ and
reverse 5′-TGGACCCGCACAGCAAAGAAGT-3′.
Primers for β-globin used as a positive control were
provided by Millipore together with ChIP quality anti-
JMJD6 antibody.
Cell cytotoxicity assay
Cells were seeded at 10,000 cells per well in 96-well
non-transparent plates. The next day, cells were treated
with 150 nM 4-hydroxytamoxifen (4-OHT) to induce
Myc or with equal volume of EtOH as a control.
Twenty-four hour later, cells were washed twice with
PBS and the media was changed for “stress media” that
included either serum-free media, glucose-free media,
glutamine-free media, or 100 μM etoposide. After 18–20
hours the percentage of dead cells relative to the total
amount of cells was measured using the luminescent
CytoTox-Glo cytotoxicity assay (Promega, USA). Briefly,
50 μl of CytoTox-Glo cytotoxicity reagent was added to
each well, mixed and incubated for 15 min at room
temperature. After measuring the luminescent signal,
50 μl of lysis reagent containing digitonin was added for
another 15 min to lyse the remaining viable cells. After in-
cubation, the second luminescence measurement was
taken and the percentage of dead cells was calculated by
dividing the first luminescence by second after subtraction
of the background signal for media only. Each experiment
was performed in triplicates and repeated 2–3 times.
The CytoTox-Glo assay measures the number of dead
cells irrespective of how cells died. To confirm that ma-
jority of cell die from apoptosis after Myc induction, we
repeated the experiments, performing FACS analysis
after staining the cells with FITC-Annexin V and propi-
dium iodide using the Apoptosis Detection Kit (BD
Pharmingen, USA). The data are shown in Additional
file 1: Figure S9.
Migration and invasion assay
2 × 104 cells expressing JMJD6 or LacZ control were
placed into the top compartment of transwell Boyden
chambers (8 μm, Corning, USA) in serum-free media. The
lower compartment contained complete media with 10 %
FBS. For the invasion assay, we used the same setting with
Matrigel™-covered chambers prepared according to the
manufacturer’s instructions (Corning, USA). After 24 h,
migrated cells were fixed and stained with the Diff-Quik
Stain Set (Dade Behring Inc., USA). The cells that mi-
grated through the pores of the membrane were photo-
graphed and quantified using ImageJ software.
Western blot analysis
Protein lysates were prepared in RIPA buffer and 20–
50 μg of protein were fractionated in a 10 % SDS-PAGE
gel and transferred to a PVDF membrane (Immobilon-P,
Millipore). The membrane was blocked with 5 % milk
(Bio-Rad Laboratories), probed with antibodies, followed
by washing and incubation with HRP-conjugated sec-
ondary antibody (Pierce) and developed using the
WesternBright ECLTM reagent (Advansta, USA). Anti-
bodies used were anti-V5 (Life Technologies, USA), anti-
p53 (Becton Dickinson, USA), anti-Myc, anti-p53-Ser15,
anti-p21 (Santa Cruz Biotechnology, USA), anti-
Caspase3, anti-PARP, anti-Bmi1, anti-Bcl2, anti-Bcl-xL,
anti-Snail, anti-Slug (Cell Signaling, USA), anti-Bcl-W
(GeneTex, USA), anti-p19ARF, anti-JMJD6 (Abcam,
USA), anti-vimentin, and anti-β-actin (Millipore, USA).
Animal studies
Cells were trypsinized and washed twice with PBS, and
106 cells in 100-μl PBS were surgically implanted into
the #4 mammary fat pad of FVB/N mice (Charles River,
USA). One week later, staples were removed and tumor
volume was measured weekly with a caliper over
1 month. For the lung colonization assay, cells were pre-
pared the same way and 5 × 105 cells in 100-μl PBS were
injected by tail vein into FVB/N mice. Three weeks later,
mice were euthanized, lungs were formalin fixed and
paraffin embedded, and sections were stained with
hematoxylin-eosin solution.
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All GEM models were described by Zhu et al. [66].
All mice were treated in accordance with the Guide
for the Care and Use of Laboratory Animals (NIH publi-
cation no. 86–23, 1985) under an animal protocol
(LCBG-063) approved by the IACUC of the National
Cancer Institute (NCI).
TUNEL assay
Lungs from mice were formalin fixed and embedded in
paraffin, and three 5-μm step sections were obtained for
each lung. Sections were deparaffinized by standard
treatment with xylene and ethanol. The following pro-
cedure was performed using the ApopTag Peroxidase In
Situ Apoptosis Detection Kit (Millipore, USA) according
to the manufacturer’s instructions. Briefly, the tissue was
pretreated with proteinase K (20 μg/ml), endogenous
peroxidase was quenched by 3 % hydrogen peroxide for
5 min, and slides were incubated with TdT enzyme for 1 h
at 37 °C. After washing, slides were incubated with anti-
digoxigenin conjugate for 30 min at room temperature,
washed and developed with peroxidase substrate. Slides
were counterstained with methyl green and after dehydra-
tion mounted under glass coverslips using Permount
media (Fisher Scientific, USA). Three photographs were
taken from each slide and analyzed using ImageJ software.
Immunofluorescence
Cells expressing JMJD6 or LacZ were grown on cover
slips, fixed with 4 % paraformaldehyde for 15 min, and
permeabilized with 0.2 % Triton X-100 for 4 min, and
immunostaining was performed by 1-h incubation with
anti-V5 antibody (Life Technologies, USA) followed by
30-min incubation with the secondary goat anti-mouse
antibody, conjugated with Alexa Fluor 568 (Life
Technologies, USA). Nuclei were counterstained with
DAPI and images were taken with Nikon Eclipse E800
fluorescent microscope (Nikon).
Statistical analysis
Statistical analysis was performed with GraphPad Prism5
software that shows mean values with 95 % confidence
interval. The p values were calculated using Student’s t
test (two tailed). The TaqMan data were analyzed using
ΔΔCt method and presented as mean fold change
±SEM. The Pearson correlation coefficient for mouse
mammary gland tumors was determined to assess the
correlation of JMJD6 and p19ARF expressions.
The expression data for JMJD6 and Myc in human
mammary gland tumors were obtained from the
METABRIC [69]. For each gene, the binary expression
values (high or low) were defined by dichotomizing con-
tinuous expression values using the median as the
threshold. We used the two genes JMJD6 and Myc
jointly to define four patient sub-groups: JMJD6 high/
Myc low, JMJD6 low/Myc low, JMJD6 high/Myc high,
and JMJD6 low/Myc high. To examine the effect of
JMJD6, we compared the Kaplan-Meier curves between
the two sub-groups JMJD6 high/Myc low versus JMJD6
low/Myc low. We also compared JMJD6 high/Myc high
versus JMJD6 low/Myc high. p values were obtained
using log-rank test.
Additional files
Additional file 1: Figures S1–S9. Figure S1. The genome locus
coordinates and number of genes in the minimal region of chromosome
11 amplicon in MMTV-Myc mammary gland tumors. Figure S2. CGH
analysis of two cell lines derived from MMTV-Myc mammary gland
umors. A. Chromosomal gains and losses in Myc83 and 88CT1 cell lines.
Arrow indicates the chromosome 11 amplicon in Myc83 cells consistent
with the original CNV observations made in Fig. 1 for MMTV-Myc tumors.
88CT1 cells do not contain this amplicon. B. RT-qPCR validation of higher
expression of three genes contained within the amplified region in
Myc83 compared to 88CT1 cells. Figure S3. Analysis of cell death induced
by glucose deprivation or etoposide treatment in cells with knock-down
of 6 genes contained within the amplified region of chromosome 11.
Analysis was performed as in Fig. 3 using cells with stable expression of
shRNAs targeting the FBF1, Ube2o, Birc5, TK1, Sumo2, and Tnrc6c genes.
Originally, 5 shRNAs for each gene were tested and shRNAs that achieved
more than a 50 % downregulation of the targeted gene were selected
for further analysis. Myc was induced in NMuMG cells expressing pBabe-
MycERTM by the addition of 150 nM 4-OHT (MycON) for 24 h. Myc-
induced cell death was tested after treatment with 100 μM etoposide for
20 h. Figure S4. Efficiency of JMJD6 knock-down. Western blot analysis of
JMJD6 expression in NMuMG and Myc83 cell lines stably expressing two
different shRNA vectors. Figure S5. Ectopic expression of LacZ-V5 and
JMJD6-V5 in NMuMG cells. A. Cells were stained with anti-V5 antibody,
followed by incubation with a secondary antibody conjugated with
Alexa-568 and DAPI. The images show nuclear localization for JMJD6 and
cytoplasmic localization for LacZ. B. Western blot analysis of cells with
JMJD6 overexpression using anti-JMJD6 antibodies. Figure S6. JMJD6
does not alter c-Myc protein levels or localization of MycER™ fusion
protein. A. Western blot analysis of NMuMG-MycER™ cells expressing LacZ
or JMJD6 with anti-Myc antibody after addition of 4-OHT. Left panel
shows MycER™ fusion protein and right panel shows endogenous c-Myc
protein in cells expressing LacZ or JMJD6. B. Immunofluorescent staining
(anti-c-Myc antibody) of NMuMG-MycER™ cells expressing JMJD6 after
treatment with 4-OHT (MycON) or ethanol (MycOFF) for 24 h. Figure S7.
Reverse transcription-qPCR analysis of JMJD6 and p19ARF expression in
mouse MMTV-Myc mammary gland tumors. RNA isolated from mammary
gland tumors was processed as described in the “Methods” section. The
ΔCT values for JMJD6 and p19ARF were normalized to mouse Tbp
housekeeping gene expression. Figure S8. JMJD6 does not bind to p16
promoter in NMuMG cells. Primers for mouse p16 gene promoter were
used as a negative control after chromatin immunoprecipitation with
anti-JMJD6 antibody described in Fig. 7. Figure S9. Wild-type JMJD6, but
not its mutant form, suppresses Myc-induced apoptotic cell death. The
experiments were performed as described in Fig. 4. The percentage of
dead cells was measured by FACS analysis of cells stained with Annexin V
and propidium iodide. (PPTX 2558 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
In this report, OA designed and performed the experiments and wrote the
manuscript. JG designed the experiments and wrote the manuscript. KC. LeT,
JH, MZ, and CBG performed the experiments. TQ assisted with animal
studies. HY and ML performed the bioinformatics analysis. All authors read
and approved the final manuscript.
Aprelikova et al. Clinical Epigenetics  (2016) 8:38 Page 14 of 16
Acknowledgements
This work was supported by the Intramural Research Program of the NIH,
CCR, and NCI. We would like to thank Dr. Evan and Dr. Lazebnik for pBabe-
MycERTM puro and hygro plasmids, Dr. Desai for pLV-JMJD6 and LacZ
plasmids, Dr. Johnson for pBabe-p19ARF plasmid, Dr. Liu for depositing data
into Gene Expression Omnibus, and members of Green lab for helpful
discussions. We are grateful to Dr. Kent Hunter for critical reading of the
manuscript. We would also like to thank the Array Core Facility of the
National Cancer Institute for performing array CGH analysis.
Received: 28 January 2016 Accepted: 6 April 2016
References
1. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, et al. The
C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal
epithelial cell targeting with multistage progression to carcinoma.
Oncogene. 2000;19:1020–7.
2. Hennighausen L. Mouse models for breast cancer. Oncogene. 2000;19:966–7.
3. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al.
Identification of conserved gene expression features between murine
mammary carcinoma models and human breast tumors. Genome Biol.
2007;8:R76.
4. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al.
Germline BRCA1 mutations and a basal epithelial phenotype in breast
cancer. J Natl Cancer Inst. 2003;95:1482–5.
5. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated
observation of breast tumor subtypes in independent gene expression data
sets. Proc Natl Acad Sci U S A. 2003;100:8418–23.
6. Inaki K, Menghi F, Woo XY, Wagner JP, Jacques PE, Lee YF, et al. Systems
consequences of amplicon formation in human breast cancer. Genome Res.
2014;24:1559–71.
7. Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A, et al.
Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse
phenotypes including metastatic potential. Proc Natl Acad Sci U S A. 2009;
106:16387–92.
8. Silva GO, He X, Parker JS, Gatza ML, Carey LA, Hou JP, et al. Cross-species
DNA copy number analyses identifies multiple 1q21-q23 subtype-specific
driver genes for breast cancer. Breast Cancer Res Treat. 2015;152:347–56.
9. Alitalo K, Schwab M. Oncogene amplification in tumor cells. Adv Cancer
Res. 1986;47:235–81.
10. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer. 2000;7:
143–64.
11. Nesbit CE, Tersak JM, Prochownik EV. Myc oncogenes and human
neoplastic disease. Oncogene. 1999;18:3004–16.
12. Shiu RP, Watson PH, Dubik D. c-Myc oncogene expression in estrogen-
dependent and -independent breast cancer. Clin Chem. 1993;39:353–5.
13. Hodgson JG, Malek T, Bornstein S, Hariono S, Ginzinger DG, Muller WJ, et al.
Copy number aberrations in mouse breast tumors reveal loci and genes
important in tumorigenic receptor tyrosine kinase signaling. Cancer Res.
2005;65:9695–704.
14. McCormack SJ, Weaver Z, Deming S, Natarajan G, Torri J, Johnson MD, et al.
Myc/p53 interactions in transgenic mouse mammary development,
tumorigenesis and chromosomal instability. Oncogene. 1998;16:2755–66.
15. Montagna C, Lyu MS, Hunter K, Lukes L, Lowther W, Reppert T, et al. The
septin 9 (MSF) gene is amplified and overexpressed in mouse mammary
gland adenocarcinomas and human breast cancer cell lines. Cancer Res.
2003;63:2179–87.
16. Weaver Z, Montagna C, Xu X, Howard T, Gadina M, Brodie SG, et al.
Mammary tumors in mice conditionally mutant for Brca1 exhibit gross
genomic instability and centrosome amplification yet display a recurring
distribution of genomic imbalances that is similar to human breast cancer.
Oncogene. 2002;21:5097–107.
17. Liu ML, Shibata MA, Von Lintig FC, Wang W, Cassenaer S, Boss GR, et al.
Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40
Tag transgenic mice. Oncogene. 2001;20:2044–9.
18. Liu ML, Von Lintig FC, Liyanage M, Shibata MA, Jorcyk CL, Ried T, et al.
Amplification of Ki-ras and elevation of MAP kinase activity during
mammary tumor progression in C3(1)/SV40 Tag transgenic mice. Oncogene.
1998;17:2403–11.
19. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, et al.
Detection and mapping of amplified DNA sequences in breast cancer by
comparative genomic hybridization. Proc Natl Acad Sci U S A. 1994;91:
2156–60.
20. Somiari SB, Shriver CD, He J, Parikh K, Jordan R, Hooke J, et al. Global search
for chromosomal abnormalities in infiltrating ductal carcinoma of the breast
using array-comparative genomic hybridization. Cancer Genet Cytogenet.
2004;155:108–18.
21. Toffoli S, Bar I, Abdel-Sater F, Delree P, Hilbert P, Cavallin F, et al.
Identification by array comparative genomic hybridization of a new
amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple
negative breast cancer. Breast Cancer Res. 2014;16:466.
22. Waldman FM, DeVries S, Chew KL, Moore 2nd DH, Kerlikowske K, Ljung BM.
Chromosomal alterations in ductal carcinomas in situ and their in situ
recurrences. J Natl Cancer Inst. 2000;92:313–20.
23. Weaver ZA, McCormack SJ, Liyanage M, du Manoir S, Coleman A, Schrock E,
et al. A recurring pattern of chromosomal aberrations in mammary gland
tumors of MMTV-cMyc transgenic mice. Genes Chromosomes Cancer. 1999;
25:251–60.
24. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified
oestrogen receptor ligand-binding domain as an improved switch for the
regulation of heterologous proteins. Nucleic Acids Res. 1995;23:1686–90.
25. Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, et al. JMJD6 is a
driver of cellular proliferation and motility and a marker of poor prognosis
in breast cancer. Breast Cancer Res. 2012;14:R85.
26. Wang F, He L, Huangyang P, Liang J, Si W, Yan R, et al. JMJD6 promotes
colon carcinogenesis through negative regulation of p53 by hydroxylation.
PLoS Biol. 2014;12, e1001819.
27. Zhang J, Ni SS, Zhao WL, Dong XC, Wang JL. High expression of JMJD6
predicts unfavorable survival in lung adenocarcinoma. Tumour Biol. 2013;34:
2397–401.
28. Poulard C, Rambaud J, Lavergne E, Jacquemetton J, Renoir JM, Tredan O, et
al. Role of JMJD6 in breast tumourigenesis. PLoS One. 2015;10, e0126181.
29. Unoki M, Masuda A, Dohmae N, Arita K, Yoshimatsu M, Iwai Y, et al. Lysyl 5-
hydroxylation, a novel histone modification, by Jumonji domain containing
6 (JMJD6). J Biol Chem. 2013;288:6053–62.
30. Webby CJ, Wolf A, Gromak N, Dreger M, Kramer H, Kessler B, et al. Jmjd6
catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA
splicing. Science. 2009;325:90–3.
31. Boeckel JN, Guarani V, Koyanagi M, Roexe T, Lengeling A, Schermuly RT, et
al. Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic
sprouting and regulates splicing of VEGF-receptor 1. Proc Natl Acad Sci U S
A. 2011;108:3276–81.
32. Liu W, Ma Q, Wong K, Li W, Ohgi K, Zhang J, et al. Brd4 and JMJD6-
associated anti-pause enhancers in regulation of transcriptional pause
release. Cell. 2013;155:1581–95.
33. Chen D, Kon N, Zhong J, Zhang P, Yu L, Gu W. Differential effects on ARF
stability by normal versus oncogenic levels of c-Myc expression. Mol Cell.
2013;51:46–56.
34. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and
stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor
suppression pathways. Cell. 1998;92:725–34.
35. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, et al. Myc
signaling via the ARF tumor suppressor regulates p53-dependent apoptosis
and immortalization. Genes Dev. 1998;12:2424–33.
36. Chang B, Chen Y, Zhao Y, Bruick RK. JMJD6 is a histone arginine
demethylase. Science. 2007;318:444–7.
37. Wysocka J, Allis CD, Coonrod S. Histone arginine methylation and its
dynamic regulation. Front Biosci. 2006;11:344–55.
38. Xu X, Hoang S, Mayo MW, Bekiranov S. Application of machine learning
methods to histone methylation ChIP-Seq data reveals H4R3me2 globally
represses gene expression. BMC Bioinf. 2010;11:396.
39. Li X, Hu X, Patel B, Zhou Z, Liang S, Ybarra R, et al. H4R3 methylation
facilitates beta-globin transcription by regulating histone acetyltransferase
binding and H3 acetylation. Blood. 2010;115:2028–37.
40. Yang Y, Lu Y, Espejo A, Wu J, Xu W, Liang S, et al. TDRD3 is an
effector molecule for arginine-methylated histone marks. Mol Cell. 2010;
40:1016–23.
41. Beverly LJ, Varmus HE. Myc-induced myeloid leukemogenesis is accelerated
by all six members of the antiapoptotic BCL family. Oncogene. 2009;28:
1274–9.
Aprelikova et al. Clinical Epigenetics  (2016) 8:38 Page 15 of 16
42. Eischen CM, Packham G, Nip J, Fee BE, Hiebert SW, Zambetti GP, et al. Bcl-2
is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene.
2001;20:6983–93.
43. Shiio Y, Suh KS, Lee H, Yuspa SH, Eisenman RN, Aebersold R. Quantitative
proteomic analysis of Myc-induced apoptosis: a direct role for Myc
induction of the mitochondrial chloride ion channel, mtCLIC/CLIC4. J Biol
Chem. 2006;281:2750–6.
44. D’Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, et al.
c-Myc induces mammary tumorigenesis by means of a preferred pathway
involving spontaneous Kras2 mutations. Nat Med. 2001;7:235–9.
45. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary
adenocarcinomas in transgenic mice that carry and express MTV/Myc fusion
genes. Cell. 1984;38:627–37.
46. Liu H, Radisky DC, Yang D, Xu R, Radisky ES, Bissell MJ, et al. Myc suppresses
cancer metastasis by direct transcriptional silencing of alphav and beta3
integrin subunits. Nat Cell Biol. 2012;14:567–74.
47. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al.
Induction of apoptosis in fibroblasts by c-Myc protein. Cell. 1992;69:119–28.
48. Felsher DW, Bishop JM. Transient excess of Myc activity can elicit genomic
instability and tumorigenesis. Proc Natl Acad Sci U S A. 1999;96:3940–4.
49. Gibson AW, Cheng T, Johnston RN. Apoptosis induced by c-Myc overexpression
is dependent on growth conditions. Exp Cell Res. 1995;218:351–8.
50. Hoffman B, Liebermann DA. Apoptotic signaling by c-Myc. Oncogene. 2008;
27:6462–72.
51. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer.
Oncogene. 2003;22:9007–21.
52. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the
ARF-MDM2-p53 tumor suppressor pathway in Myc-induced
lymphomagenesis. Genes Dev. 1999;13:2658–69.
53. Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53.
Science. 1994;265:2091–3.
54. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW.
INK4a/ARF mutations accelerate lymphomagenesis and promote
chemoresistance by disabling p53. Genes Dev. 1999;13:2670–7.
55. Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O, et al. Myc-ARF
(alternate reading frame) interaction inhibits the functions of Myc. J Biol
Chem. 2004;279:36698–707.
56. Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR. p19ARF directly and
differentially controls the functions of c-Myc independently of p53. Nature.
2004;431:712–7.
57. Poulard C, Rambaud J, Hussein N, Corbo L, Le Romancer M. JMJD6
regulates ERalpha methylation on arginine. PLoS One. 2014;9, e87982.
58. Heim A, Grimm C, Muller U, Haussler S, Mackeen MM, Merl J, et al. Jumonji
domain containing protein 6 (JMJD6) modulates splicing and specifically
interacts with arginine-serine-rich (RS) domains of SR- and SR-like proteins.
Nucleic Acids Res. 2014;42:7833–50.
59. Qi JW, Qin TT, Xu LX, Zhang K, Yang GL, Li J, et al. TNFSF15 inhibits
vasculogenesis by regulating relative levels of membrane-bound and
soluble isoforms of VEGF receptor 1. Proc Natl Acad Sci U S A. 2013;110:
13863–8.
60. Alsarraj J, Faraji F, Geiger TR, Mattaini KR, Williams M, Wu J, et al. BRD4 short
isoform interacts with RRP1B, SIPA1 and components of the LINC complex
at the inner face of the nuclear membrane. PLoS One. 2013;8, e80746.
61. Rahman S, Sowa ME, Ottinger M, Smith JA, Shi Y, Harper JW, et al. The Brd4
extraterminal domain confers transcription activation independent of pTEFb
by recruiting multiple proteins, including NSD3. Mol Cell Biol. 2011;31:2641–52.
62. Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET
bromodomain inhibition. Mol Cell. 2014;54:728–36.
63. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, et al. c-Myc
regulates transcriptional pause release. Cell. 2010;141:432–45.
64. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al.
Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;
151:56–67.
65. Le Romancer M, Treilleux I, Leconte N, Robin-Lespinasse Y, Sentis S,
Bouchekioua-Bouzaghou K, et al. Regulation of estrogen rapid signaling
through arginine methylation by PRMT1. Mol Cell. 2008;31:212–21.
66. Zhu M, Yi M, Kim CH, Deng C, Li Y, Medina D, et al. Integrated miRNA and
mRNA expression profiling of mouse mammary tumor models identifies
miRNA signatures associated with mammary tumor lineage. Genome Biol.
2011;12:R77.
67. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency
in glutamine but not glucose induces Myc-dependent apoptosis in human
cells. J Cell Biol. 2007;178:93–105.
68. Zheng Y, Zhao YD, Gibbons M, Abramova T, Chu PY, Ash JD, et al. Tgfbeta
signaling directly induces ARF promoter remodeling by a mechanism
involving Smads 2/3 and p38 MAPK. J Biol Chem. 2010;285:35654–64.
69. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The
genomic and transcriptomic architecture of 2,000 breast tumours reveals
novel subgroups. Nature. 2012;486:346–52.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Aprelikova et al. Clinical Epigenetics  (2016) 8:38 Page 16 of 16
